CJC-1295 WITH DAC

Long-Acting GHRH Analog for Sustained Endocrine Research

CJC-1295 (with DAC) is a 30-amino acid analog of human growth hormone-releasing hormone (GHRH) that incorporates a proprietary Drug Affinity Complex (DAC). The DAC moiety consists of a reactive maleimidopropionyl group that forms a stable, covalent bond with the free cysteine-34 residue of circulating serum albumin following administration. This albumin binding dramatically extends the peptide’s half-life from minutes (like native GHRH) to approximately 6-8 days in research models, creating a sustained-release reservoir of GHRH activity. As a research tool, CJC-1295 (DAC) allows scientists to investigate the effects of continuous, prolonged GHRH receptor stimulation on the pituitary, leading to sustained elevation of both growth hormone and insulin-like growth factor 1 (IGF-1) levels. This makes it invaluable for studying chronic hormone exposure paradigms, tissue growth over extended periods, and the long-term metabolic consequences of elevated GH/IGF-1 in experimental models.

Complete Research Kit Contents & Verification

Each research order provides a complete experimental package designed for long-term endocrine research:

• Primary Research Compound: 10 sterile glass vials containing 5mg of lyophilized CJC-1295 (with DAC) peptide powder per vial.

• Reconstitution Solution: 30ml vial of sterile Bacteriostatic Water (0.9% Benzyl Alcohol) for experimental use.

• Laboratory Administration Tools: Pack of sterile syringes (1ml for precise dosing, 3ml for reconstitution) with various gauges and alcohol swabs.

• Research Protocol Documentation:

  • Dosing Schedule: Administration protocol specifically designed for this long-acting compound, featuring less frequent dosing intervals (e.g., once or twice weekly in chronic models) compared to short-acting peptides.

  • Usage INSTRUCTIONS (CRITICAL): Comprehensive guide covering the unique handling of this albumin-binding peptide: gentle reconstitution to preserve the reactive DAC moiety, immediate use after reconstitution (due to reactivity), avoidance of contact with surfaces containing free thiols, and storage guidelines (-20°C or below, protect from light).

• Quality Verification: Certificate of Analysis (CoA) provided with each batch, detailing:

  • Purity Analysis (>97% by HPLC – complexity due to DAC)

  • Structural Verification (Mass Spectrometry):

    • Full GHRH analog sequence confirmation

    • Critical: Verification of intact Drug Affinity Complex (DAC) attachment – the defining feature.

  • Molecular Weight Confirmation (~4050 Da with DAC, approximate)

  • Sterility Testing Results

  • Endotoxin Levels (<10 EU/mg)

  • Free Maleimide Content / DAC Reactivity Assay

  • Residual Solvents

  • Note: The DAC modification is reactive. The CoA confirms it is intact and active at time of shipment.

Research Applications & Scientific Utility

In a laboratory setting, CJC-1295 (DAC) enables unique investigation into sustained endocrine stimulation. Primary research applications include:

• Chronic Exposure Models: Studying the long-term effects of elevated GH/IGF-1 on tissue growth, metabolism, and organ function over weeks or months with minimal interventions.

• Aging Research: Investigating the potential of sustained GH/IGF-1 elevation to reverse or mitigate age-related declines in lean mass, bone density, and skin thickness in animal models of aging.

• Wound Healing & Tissue Repair: Researching the effects of continuous anabolic stimulation on chronic wound models, fracture healing, or muscle injury recovery.

• Comparative Endocrinology: Serving as a direct comparator to pulsatile GH secretagogues (like Ipamorelin) or exogenous GH administration to contrast the effects of continuous vs. pulsatile hormone delivery.

• Metabolic Studies: Exploring the long-term metabolic adaptations (both beneficial and adverse, like insulin resistance) to chronically elevated GH/IGF-1.

Laboratory Handling & Safety Protocol – EXTREME CAUTION

• Storage: Store unopened vials at -20°C or preferably -80°C, protected from light and moisture. The DAC moiety is sensitive. Once reconstituted, use immediately. Do not store reconstituted solution.

• Reconstitution: Time-sensitive procedure. Use cold bacteriostatic water. Gently swirl to dissolve. Do not shake. The solution must be used within a very short timeframe (minutes) to prevent hydrolysis of the reactive maleimide group before administration in the research model.

• Reactivity Warning: The DAC contains a maleimide group that covalently binds to free thiols (-SH). Avoid contact with reducing agents (e.g., DTT, BME) or surfaces. Use fresh, clean syringes.

• Laboratory Safety: Wear appropriate PPE. This is a reactive biochemical. Handle with extreme care.

⚠️ Critical Compliance & Intended Use Disclaimer:

THIS PRODUCT IS SOLD FOR RESEARCH USE ONLY (RUO). NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

1. Intended Use: CJC-1295 (with DAC) is supplied as a specialized biochemical reagent for laboratory research purposes only. It is intended for use by qualified researchers in controlled settings studying sustained hormone action. The “dosing schedule” is for research models only.

2. Not for Human Consumption: Under no circumstances is this product intended for human or animal administration. It is not a performance-enhancing, anti-aging, or bodybuilding substance. The reactive DAC moiety makes it particularly unsuitable and dangerous for human use.

3. Regulatory Status: This product has not been evaluated or approved by any health authority for any use. It is an investigational research compound.

4. Critical Distinction: Researchers must understand this is CJC-1295 WITH DAC (long-acting) and is chemically and pharmacologically distinct from CJC-1295 without DAC (short-acting). Using the wrong one invalidates research.

5. Researcher Responsibility: The purchaser assumes all risk and responsibility for safe handling, proper experimental design, and compliance with all laws regarding this reactive research compound.